Hepatic steatosis promotes liver metastasis
Hepatic steatosis promotes liver metastasis
批准号:
10365691
负责人:
Steven L Teitelbaum
金额:
$45.72万
依托单位:
依托单位国家:
美国
项目类别:
财政年份:
2022
资助国家:
美国
项目状态:
未结题
起止时间:
2022-01-01 至 2026-11-30
关键词:
AddressAdipose tissueAffectAmericanBreast Cancer PatientBreast Cancer Risk FactorBreast Cancer TreatmentBreast cancer metastasisCaloriesCancer PrognosisDataDiagnosisDisseminated Malignant NeoplasmEarly treatmentEnergy-Generating ResourcesEnvironmentEnzymesEventExhibitsFatty AcidsFatty LiverGoalsGrantGrowthHealthHepaticHepatocyteHigh Fat DietHistologyHumanImmuneInstitutesIntakeLipidsLipolysisLiverMagnetic Resonance ImagingMalignant NeoplasmsMetabolicMetabolic syndromeMetastatic Neoplasm to the LiverMetastatic breast cancerMitochondriaModelingMusNeoplasm MetastasisObesityPatientsPhenotypePredispositionPreventionProcessPrognosisPropertyResistanceRoleSiteSocietiesTherapeuticTissue TransplantationTriglyceridesTumor BurdenTumor-associated macrophagesWeightWomanbreast cancer survivalcancer cellchemotherapyfatty liver diseaseglucose metabolismimprovedliver biopsymacrophagemalignant breast neoplasmneoplastic cellnon-alcoholic fatty liver diseaseoxidationpreventresponsetargeted treatmenttumortumor growthtumor microenvironment
中文摘要
项目概要/摘要
早期乳腺癌的治疗已经有了很大的改善,但预防转移仍然是一个更重要的问题。
难以捉摸的目标肥胖是我们社会中的一种地方病,与乳腺癌风险增加有关
和加速的转移。肥胖影响乳腺癌患者生存的方式是,
然而,人们对此知之甚少。肝脏是乳腺癌最常见的转移部位之一,
其发生通常与不良预后相关。肝脏健康与体重密切相关,因为肥胖是
脂肪肝的主要原因,估计存在于1/4到1/3的美国人中。
我们发现,脂肪肝疾病通过为肿瘤提供燃料,
细胞加速生长。对人类肝脏活检和MRI分析的检查也表明了这一点
在患有转移性乳腺癌的女性中也是如此。因此,我们的第一个目标是确定治疗脂肪肝是否
减少乳腺癌肝转移并改善其对化疗的反应。以确定潜在的新
肝转移的治疗,我们将探讨脂肪肝疾病刺激肿瘤的机制
增长最后,我们会问,人类乳腺癌是否表现出与那些出现肝转移的人相同的肝转移特性。
对小鼠如果我们的结论被证明是正确的,那么乳腺癌的治疗将普遍需要预防和治疗。
脂肪肝的发病率,因此影响所有受影响的女性。脂肪肝的预防和治疗
然而,乳腺癌患者可能会减少肝转移,从而延长生存期。因为胖子
肝病最常见的是肥胖的产物,教育患者卡路里摄入量,这可以制定
立即,可能对乳腺癌预后有显着影响。
英文摘要
Project Summary/Abstract
Treatment of early stage breast cancer has substantially improved but preventing metastasis remains a more
elusive target. Obesity, which is endemic in our society, is associated with an increased risk of breast cancer
and accelerated metastasis. The means by which obesity compromises survival of breast cancer patients is,
however, poorly understood. Liver is among the most common sites of breast cancer metastasis and its
occurrence is generally associated with poor prognosis. Liver health is closely related to weight as obesity is the
major cause of fatty liver disease, estimated to be present in 1/4 to 1/3 of Americans.
We discovered that fatty liver disease markedly increases liver metastasis, in mice, by providing fuel to tumor
cells thereby accelerating their growth. Examination of human liver biopsies and MRI analysis suggests the same
is true in women with metastatic breast cancer. Thus, our first goal is to determine if treating fatty liver disease
reduces breast cancer liver metastasis and improves its response to chemotherapy. To identify potential new
treatments for liver metastasis we will explore the mechanisms by which fatty liver disease stimulates tumor
growth. Finally, we will ask if human breast cancers exhibit the same liver metastatic properties as those arising
in mice. If our conclusion proves true, treatment of breast cancer will universally require prevention and treatment
of fatty liver disease and therefore impact all affected women. Prevention and treatment of fatty liver disease in
breast cancer patients, however, may likely reduce liver metastasis and therefore prolong survival. Because fatty
liver disease is most often the product of obesity, educating patients about calorie intake, which can be instituted
immediately, may have significant effects on breast cancer prognosis.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Hepatic steatosis promotes liver metastasis
-
批准号:10545090
-
项目类别:
-
资助金额:$47.08万
-
财政年份:2022
-
负责人:Steven L Teitelbaum
-
依托单位:
FAT TALKS TO BONE
-
批准号:9978044
-
项目类别:
-
资助金额:$38.13万
-
财政年份:2017
-
负责人:Steven L Teitelbaum
-
依托单位:
FAT TALKS TO BONE
-
批准号:10163838
-
项目类别:
-
资助金额:$38.13万
-
财政年份:2017
-
负责人:Steven L Teitelbaum
-
依托单位:
FAT TALKS TO BONE
-
批准号:9526487
-
项目类别:
-
资助金额:$38.13万
-
财政年份:2017
-
负责人:Steven L Teitelbaum
-
依托单位:
FAT TALKS TO BONE
-
批准号:9754825
-
项目类别:
-
资助金额:$38.13万
-
财政年份:2017
-
负责人:Steven L Teitelbaum
-
依托单位:
Mechanisms of Rankl Mediated Osteoclast Activation
-
批准号:7812306
-
项目类别:
-
资助金额:$43.87万
-
财政年份:2009
-
负责人:Steven L Teitelbaum
-
依托单位:
MECHANISMS OF POLARIZED SECRETION BY BONE CELLS
-
批准号:7858352
-
项目类别:
-
资助金额:$33.86万
-
财政年份:2009
-
负责人:Steven L Teitelbaum
-
依托单位:
CDC 42 BIM AND THE OSTEOCLAST
-
批准号:7729102
-
项目类别:
-
资助金额:$38.0万
-
财政年份:2009
-
负责人:Steven L Teitelbaum
-
依托单位:
MECHANISMS OF POLARIZED SECRETION BY BONE CELLS
-
批准号:7633796
-
项目类别:
-
资助金额:$34.2万
-
财政年份:2009
-
负责人:Steven L Teitelbaum
-
依托单位:
Mechanisms of Polarized Secretion by Bone Cells
-
批准号:8274354
-
项目类别:
-
资助金额:$32.5万
-
财政年份:2009
-
负责人:Steven L Teitelbaum
-
依托单位:
Mechanisms of Polarized Secretion by Bone Cells
-
批准号:8493782
-
项目类别:
-
资助金额:$30.88万
-
财政年份:2009
-
负责人:Steven L Teitelbaum
-
依托单位:
Mechanisms of Polarized Secretion by Bone Cells
-
批准号:8076266
-
项目类别:
-
资助金额:$32.5万
-
财政年份:2009
-
负责人:Steven L Teitelbaum
-
依托单位:
CDC 42 BIM AND THE OSTEOCLAST
-
批准号:7934686
-
项目类别:
-
资助金额:$37.82万
-
财政年份:2009
-
负责人:Steven L Teitelbaum
-
依托单位:
RANK Ligand is a Bone Anabolic Agent
-
批准号:6508327
-
项目类别:
-
资助金额:$34.91万
-
财政年份:2002
-
负责人:Steven L Teitelbaum
-
依托单位:
RANK Ligand is a Bone Anabolic Agent
-
批准号:6933118
-
项目类别:
-
资助金额:$34.23万
-
财政年份:2002
-
负责人:Steven L Teitelbaum
-
依托单位:
RANK Ligand is a Bone Anabolic Agent
-
批准号:7118802
-
项目类别:
-
资助金额:$33.43万
-
财政年份:2002
-
负责人:Steven L Teitelbaum
-
依托单位:
RANK Ligand is a Bone Anabolic Agent
-
批准号:6630326
-
项目类别:
-
资助金额:$37.1万
-
财政年份:2002
-
负责人:Steven L Teitelbaum
-
依托单位:
RANK Ligand is a Bone Anabolic Agent
-
批准号:6792769
-
项目类别:
-
资助金额:$37.1万
-
财政年份:2002
-
负责人:Steven L Teitelbaum
-
依托单位:
MECHANISMS OF AVB3 INTEGRIN MEDIATED BONE RESORPTION
-
批准号:6349974
-
项目类别:
-
资助金额:$30.17万
-
财政年份:2000
-
负责人:Steven L Teitelbaum
-
依托单位:
MECHANISMS OF AVB3 INTEGRIN MEDIATED BONE RESORPTION
-
批准号:6826568
-
项目类别:
-
资助金额:$13.58万
-
财政年份:2000
-
负责人:Steven L Teitelbaum
-
依托单位:
海外基金